ICL Acquires Majority of Lavie Bio's Activities and Assets from Evogene

July 8, 2025

ICL Group Ltd. has completed the acquisition of the majority of activities and assets of Lavie Bio Ltd., Evogene's ag-biologicals subsidiary, including Lavie Bio's BDD technology platform, microbial bank, pipeline and current commercial products. Evogene also transferred its MicroBoost AI tech-engine for agriculture to ICL as part of the divestiture; Lavie Bio core personnel will move to ICL while certain strategic partnerships remain with Lavie Bio.

Buyers
ICL Group Ltd.
Targets
Lavie Bio Ltd.
Sellers
Evogene Ltd.
Industry
Biotechnology
Location
Israel
Transaction Type
Divestiture

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.